2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
121
Neoplasm Metastasis
12
Prostate Cancer Metastatic
4
Oligometastatic Prostate Cancer
3
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
3
Metastatic Hormone-sensitive Prostate Cancer
3
Adenocarcinoma
3
Radiation Injuries
2
Prostatic Diseases
2
Prostate CA
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms
2
Metastatic Castration-resistant Prostate Cancer
2
Urologic Diseases
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Stage IV Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Salivary Gland Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
PSA Level Greater Than 0.03
1
Oligorecurrent and Oligoprogressive Prostate Cancer Patients
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Neoplasm Recurrence, Local
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone-Sensitive Prostate Cance
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-sensitive Prostate Cancer
1
Interventions
Radiotherapy
3
Cisplatin
3
Fluorouracil
2
tislelizumab
1
pembrolizumab
1
motexafin gadolinium
1
Tamoxifen
1
Talaporfin
1
TP protocol
1
Spinal Puncture
1
Rhenium
1
Radiosurgery
1
Poly I-C
1
Paclitaxel
1
Oxaliplatin
1
Mitomycin
1
Lomustine
1
Irinotecan
1
Gemcitabine
1
Gadolinium
1
Folfox protocol
1
Ethiodized Oil
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cetuximab
1
Carboplatin
1
Blood Specimen Collection
1
Bevacizumab
1
Anesthesia, General
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Recurrence, Local
×
Androgen Antagonists
×
Clear all
NCT07483658
2026-03-19
HYP-OP-RT
CHU de Quebec-Universite Laval
Phase NA
Not yet recruiting
434 enrolled